ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial

H. Watz (Grosshansdorf, Germany), H. Magnussen (Grosshansdorf, Germany), R. Rodriguez-Roisin (Barcelona, Spain), K. Tetzlaff (Ingelheim am Rhein, Germany), M. Haensel (Ingelheim am Rhein, Germany), A. Mueller (Biberach an der Riss, Germany), C. Vogelmeier (Marburg, Germany)

Source: International Congress 2018 – Primary care management of respiratory conditions
Session: Primary care management of respiratory conditions
Session type: Oral Presentation
Number: 289
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Watz (Grosshansdorf, Germany), H. Magnussen (Grosshansdorf, Germany), R. Rodriguez-Roisin (Barcelona, Spain), K. Tetzlaff (Ingelheim am Rhein, Germany), M. Haensel (Ingelheim am Rhein, Germany), A. Mueller (Biberach an der Riss, Germany), C. Vogelmeier (Marburg, Germany). ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial. 289

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: